Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-017-3893-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ringed esophagus: all that glitters is not gold.
Rev Gastroenterol Peru
January 2025
Universidad Peruana Cayetano Heredia, Lima, Perú.
We report the case of an elderly patient with progressive dysphagia to solids and later to liquids, and weight loss. The patient underwent an upper endoscopy, which showed multiple stenoses and trachealization. Biopsies were taken and a diagnosis of lymphocytic esophagitis was made.
View Article and Find Full Text PDFAll that glitters is not gold: The false-symbol problem in archaeology.
Behav Brain Sci
January 2025
School of Liberal Arts, University of Wollongong, Wollongong,
Stibbard-Hawkes forcefully alerts us to the pitfall of false-negative reasoning in symbolic archaeology. We highlight the twin problem of false-positive reasoning in what we call the "false-symbol problem." False symbols are intuitively special entities that, owing to their non-utilitarian nature, invite symbolic interpretation.
View Article and Find Full Text PDFEchocardiographic red flags in transthyretin amyloid cardiomyopathy: all that glitters is not gold.
Eur Heart J Imaging Methods Pract
July 2024
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Via Giustiniani, 2, Padua 35128, Italy.
Multidisciplinary team meeting (MDT) in cancer care: All that glitters is not gold.
Eur J Surg Oncol
October 2024
Division of Clinical Medicine, Faculty of Health, The Medical School, Sheffield, UK; Honorary Consultant Oncoplastic Breast Surgeon, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK.
All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [Lu]Lu-PSMA-radioligand will be successful.
EJNMMI Res
October 2024
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Article Synopsis
- The study examines the low tumor doses achieved in non-prostate cancers treated with [Lu]Lu-PSMA radioligand, using a case of renal cell carcinoma as an example.
- Despite high uptake of the imaging agent [Ga]Ga-PSMA-11, treatment with [Lu]Lu-PSMA-I&T resulted in low radiation doses to tumors (0.2-0.5 Gy) and no observable treatment effect.
- The researchers suggest that the ineffective targeting may be due to PSMA receptors being located on new blood vessels rather than on tumor cells, leading to rapid washout; they propose using a radionuclide with a shorter half-life to improve treatment efficacy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!